Solid Biosciences (SLDB) Projected to Post Quarterly Earnings on Thursday

Solid Biosciences (NASDAQ:SLDB) will likely be issuing its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect the company to announce earnings of ($0.48) per share for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, March 13, 2026 at 5:00 PM ET.

Solid Biosciences Stock Performance

Shares of SLDB opened at $5.96 on Wednesday. Solid Biosciences has a fifty-two week low of $2.41 and a fifty-two week high of $7.37. The firm’s 50-day simple moving average is $6.01 and its two-hundred day simple moving average is $5.65. The stock has a market cap of $464.34 million, a PE ratio of -2.39 and a beta of 2.65.

Insider Activity at Solid Biosciences

In other news, Director Ilan Ganot sold 7,205 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $6.44, for a total transaction of $46,400.20. Following the sale, the director owned 25,271 shares of the company’s stock, valued at $162,745.24. This trade represents a 22.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Alexander Cumbo sold 16,644 shares of Solid Biosciences stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $5.82, for a total transaction of $96,868.08. Following the completion of the sale, the chief executive officer owned 235,405 shares of the company’s stock, valued at $1,370,057.10. This represents a 6.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 597,672 shares of company stock valued at $3,816,546 over the last three months. 13.63% of the stock is owned by insiders.

Institutional Investors Weigh In On Solid Biosciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Siren L.L.C. grew its position in Solid Biosciences by 3.7% in the 4th quarter. Siren L.L.C. now owns 7,690,405 shares of the company’s stock worth $43,374,000 after purchasing an additional 274,500 shares during the period. Vestal Point Capital LP boosted its stake in shares of Solid Biosciences by 95.5% in the 4th quarter. Vestal Point Capital LP now owns 5,815,000 shares of the company’s stock worth $32,797,000 after buying an additional 2,840,000 shares during the last quarter. Nantahala Capital Management LLC boosted its stake in shares of Solid Biosciences by 505.4% in the 2nd quarter. Nantahala Capital Management LLC now owns 1,703,336 shares of the company’s stock worth $8,295,000 after buying an additional 1,421,968 shares during the last quarter. Alyeska Investment Group L.P. grew its holdings in shares of Solid Biosciences by 2.6% in the third quarter. Alyeska Investment Group L.P. now owns 1,682,805 shares of the company’s stock worth $10,383,000 after acquiring an additional 41,984 shares during the period. Finally, Goldman Sachs Group Inc. increased its position in Solid Biosciences by 48.7% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,006,306 shares of the company’s stock valued at $5,676,000 after acquiring an additional 329,679 shares during the last quarter. Hedge funds and other institutional investors own 81.46% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Solid Biosciences in a research note on Thursday, January 22nd. JPMorgan Chase & Co. dropped their target price on Solid Biosciences from $13.00 to $11.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Citigroup reissued a “market outperform” rating on shares of Solid Biosciences in a research note on Wednesday, December 17th. Barclays set a $9.00 price target on Solid Biosciences and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $16.00 price target on shares of Solid Biosciences in a research note on Monday, February 9th. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $14.70.

About Solid Biosciences

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.